Increased Placenta Growth Factor in COPD
Author Information
Author(s): Cheng S-L, Wang H-C, Yu C-J, Yang P-C
Primary Institution: Far Eastern Memorial Hospital, Taiwan
Hypothesis
The effect of placenta growth factor (PlGF) in chronic obstructive pulmonary disease (COPD) is unknown.
Conclusion
The serum and BAL fluid levels of PlGF are increased in patients with COPD and are inversely correlated with FEV1.
Supporting Evidence
- Serum levels of PlGF were significantly higher in patients with COPD than in controls.
- The levels of PlGF in BAL fluid were also significantly higher in patients with COPD than in controls.
- Higher levels of PlGF correlated with worse lung function in COPD patients.
Takeaway
People with COPD have higher levels of a protein called PlGF, which might be linked to their breathing problems.
Methodology
Measured serum and BAL fluid levels of VEGF and PlGF in patients with COPD and controls, and conducted in vitro experiments on bronchial epithelial cells.
Potential Biases
The study may have bias due to the exclusion of patients with asthma or malignant lung disease.
Limitations
The study had an unbalanced gender ratio and a small sample size, particularly in severe COPD cases.
Participant Demographics
184 patients with COPD (152 men, 32 women) and control groups of smokers and non-smokers.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website